Management and Prevention of Cardio-Renal Complications in T2D
A blended learning programme of modules and webinars addressing the ongoing needs of any medical doctor involved in management of type 2 diabetes and prevention of cardio-renal complications.
The purpose of the course is to enable the learner to understand about the latest evidence-based pharmaceutical management and early diagnosis, prevention of cardio-renal complications in type 2 diabetes.
Who is this course for?
General practitioners, primary care physicians, family physicians, and any medical doctor involved in management and prevention of cardio-renal complications in type 2 diabetes.
Curriculum
Initial Self-Evaluation
Complete your initial self-evaluation before starting the course module.
1: Management Guidelines for Type 2 Diabetes in Primary Care
Learning Objectives:
At the end of this module the learner will be able to:
List the evidence-based clinical practice recommendations on prevention, diagnosis and management of T2D at primary care level
Discuss the recommendations on lifestyle and pharmacological management of T2D
Understand the management of T2D with complications, in special population, at-risk individuals and their referral
2: Glucose-Lowering Medications: Part 1
Learning Objectives
At the end of this module the learner will be able to:
Describe the pharmacology of glucose-lowering medications in diabetes
Describe the application of various glucose-lowering medications such as metformin, sulfonylureas, alpha-glucosidase inhibitors and thiazolidinediones in clinical practice
Discuss the guidelines-based approach in choosing glucose-lowering medications in the management of diabetes
3: Glucose-Lowering Medications: Part 2
Learning Objectives
At the end of this module the learner will be able to:
Discuss the pharmacology of oral glucose-lowering medications in diabetes
Describe the clinical application of various oral glucose-lowering medications including gliptins (dipeptidyl peptidase-4 inhibitor), glucagon-like peptide-1 (GLP-1) receptor agonist, sodium-glucose
cotransporter-2 (SGLT-2) inhibitors in clinical practice
Discuss guidelines-based approach in choosing oral glucose-lowering medications in the management of diabetes
Live webinar-1: The evolving landscape in the management of T2D
These terms of use (hereinafter "Terms of Use"), which we may occasionally update without prior notice, direct your access and use of the online portal www.idfdiabeteschool.org.
Access and use of this platform are currently for the exclusive use of healthcare professionals domiciled globally. Please read these terms of use carefully before registering and using the online platform of the IDF School
of Diabetes.
The information/material you receive through this platform is not intended to be, nor should it be considered to constitute medical advice of any nature. The International Diabetes Federation (hereinafter “IDF”) is not engaged
in rendering medical services, advice or recommendations to individuals with diabetes. The content provided on the IDF School of Diabetes (including the content of the online courses and additional resources) is therefore intended,
and can be used, for educational and training purposes only. It is not intended as, nor can it be considered nor does it constitute, individual medical advice and it is thus not intended to be relied upon to diagnose, treat,
cure or prevent diabetes. Although the content will provide latest evidence-based knowledge required for healthcare professionals, the IDF would recommend that participants seek further hands-on training. People with diabetes
should seek advice from and consult with qualified medical and healthcare professionals on specific situations and conditions of concern. Reasonable endeavor has been used to ensure the accuracy of the content provided on the
IDF School of Diabetes at the date of publication. However, the IDF assumes no legal liability or responsibility for the accuracy, currency or completeness of the content provided herein. Any views, opinions, and/or recommendations
are not those of the IDF or endorsed by the IDF, unless otherwise specifically indicated by the IDF. You must apply your own clinical skills and judgement in relation to anyone to whom you provide care before taking, or refraining
from, any action on the basis of the content on the IDF School of Diabetes. It is possible that our content will not always meet an individual’s own health or medical needs. The IDF cannot be held responsible for personal or other injury, loss, or damage that may result from the content contained within the online courses.
By accessing, browsing and checking the confirmation box "I agree with these terms of use", you indicate that your act is intended to serve as: (a) your acknowledgment, acceptance and consent to these terms of use; and (b) your
signing of these terms of use is to have the same strength and effect as using a manual signature.
You are responsible for periodically reviewing applicable changes to these terms of use. Your use of this platform after we post any changes to these terms of use constitutes your acceptance of such changes. If you do not agree
to these terms of use (as they may be changed occasionally) or you are not satisfied with this platform, your sole and exclusive remedy is to discontinue using this platform.
If you do not want to agree to these terms of use, you are not permitted to access or use this platform.